TABLE 3.
PrEP Assessments and Follow-Up Visits
| Assessments | Results |
|---|---|
| Clinic visits, No./total (%) | |
| Baseline | |
| HIV | 52/53 (98) |
| Sexually transmitted infection | 51/53 (96) |
| Follow up | |
| Firsta | 9/10 (90) |
| Secondb | 9/11 (82) |
| Third | 4/4 (100) |
|
| |
| Follow-up visits, median | 2 |
|
| |
| Initial PrEP regimen, No./total (%) | |
| TDF/FTC | 45/53 (85) |
| TAF/FTC | 5/53 (9) |
| Declined treatment | 3/53 (6) |
|
| |
| PrEP discontinuation, No. (%) | |
| Total | 10 (20) |
| Lost to follow-up | 4 (8) |
| Change in risk | 3 (6) |
| Veteran concern for adverse drug reactions | 2 (4) |
| Veteran moved | 1 (2) |
Abbreviations: PrEP, preexposure prophylaxis; TAF/FTC, tenofovir alafenamide/emtricitabine; TDF/FTC, tenofovir disproxil fumarate/emtricitabine.
a
HIV screening not always required at the first follow-up visit.
b
HIV screening indicated.